Furthermore, the Kaplan-Meier analysis results revealed a shorter survival time for patients with ESCC who exhibited high FZD2 expression (n = 69, median survival time = 27 months) than those who exhibited low FZD2 expression (N = 31, median survival time = 45 months; P = 0.030; Figure 1G). This evidence concerns the gene FZD2 and esophageal squamous cell carcinoma.